BioHarvest Q3 Revenue Falls to $7.9M; Going-Concern Warning on $12.5M Cash
BHST sits 22% above its 52-week low of $1.371 on light trading volume (0.3× avg).
Summary
BioHarvest reported Q3 revenue of $7.9M, down from $9.1M a year ago, and disclosed substantial doubt about its ability to continue as a going concern, with $12.5M of cash against $6.7M of nine-month operating cash burn.
Key Events · Earnings and Guidance · BHST
-
Going-Concern Warning Disclosed
Management flags a material uncertainty that raises substantial doubt about the company's ability to continue as a going concern, citing a history of operating losses and the need for additional financing.
-
Q3 Revenue Declines to $7.9M
Revenue fell to $7,867 thousand from $9,067 thousand a year ago as the company deliberately moderated Products customer acquisition; gross margin compressed to 54% from 61%.
-
Cash Burn and Liquidity
Cash and equivalents dropped to $12,491 thousand from $23,025 thousand at December 31, 2025, after $6,658 thousand of operating cash use and $1,600 thousand of capex; the nine-month net loss was $9,680 thousand.
-
CDMO Segment Loss Widens
The CDMO Services unit posted a $4,868 thousand operating loss for the nine months on $7,518 thousand of segment revenue, versus a $2,905 thousand loss a year earlier.
Analysis · BHST · Life Sciences
The interim statements carry an explicit going-concern warning, and the math explains why: nine-month operating losses of $7.4M and $6.7M of cash burned left $12.5M in the bank at September 30, and management says existing cash plus expected operating cash flow will not fund the next twelve months. Revenue is shrinking by design — Q3 fell to $7.9M from $9.1M a year ago as the company cut low-return customer acquisition — while R&D spending rose, so the path to profitability now depends on raising capital. The CDMO segment, the growth story behind the Tate & Lyle and fragrance contracts, posted a $4.9M operating loss for the nine months. With the stock at $1.67 and a $40M market cap, any equity raise would be heavily dilutive.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHST was trading at $1.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.7M. The 52-week trading range was $1.37 to $8.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.